Aviex Technologies LLC was founded
to develop a novel vaccine platform delivery technology for infectious diseases.

NEWS

April 3-6, 2023: Aviex Technologies LLC Participating in the World Vaccine Congress

Aviex Technologies LLC will be participating in the World Vaccine Congress in Washington DC. Aviex will be setting appointments for Partnership discussions at this event. Please see the contact page for ongoing conversation.

February 27, 2023: New Publication

The third publication on the Aviex drug candidate for Schistosomiasis mansoni was published by NPJ: VACCINE.
Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice
Adam S. Hassan, Se'bastien Houle, Lydia Labrie, Dilhan J. Perera, Charles M. Dozois, Brian J. Ward & Momar Ndao
Department of Microbiology and immunology, McGill University Montreal, Quebec, Canada

February 19, 2023: Update to the Board of Directors

Aviex Technologies LLC announced today that Garrett Bowden, Director of Business Development and SusAnna Bernard-Grae, Secretary of the Company, have been appointed to the Board of Directors.